{
    "organizations": [],
    "uuid": "e281bbbee48ff26b66a16ffbdae3a8963fb28b7d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-adamas-q4-loss-per-share-127/brief-adamas-q4-loss-per-share-1-27-idUSASB0C734",
    "ord_in_thread": 0,
    "title": "BRIEF-Adamas Q4 Loss Per Share $1.27",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 22 (Reuters) - Adamas Pharmaceuticals Inc:\n* ADAMAS REPORTS RECENT ACHIEVEMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2017\n* Q4 LOSS PER SHARE $1.27 * SAYS FOR 2018, ADAMAS EXPECTS FULL-YEAR RESEARCH AND DEVELOPMENT EXPENSES TO BE BETWEEN $45 MILLION AND $50 MILLION\n* QUARTERLY TOTAL NET REVENUES $568,000 VERSUS $37,000 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-23T05:03:00.000+02:00",
    "crawled": "2018-02-23T16:07:40.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "adamas",
        "pharmaceutical",
        "inc",
        "adamas",
        "report",
        "recent",
        "achievement",
        "financial",
        "result",
        "fourth",
        "quarter",
        "q4",
        "loss",
        "per",
        "share",
        "say",
        "adamas",
        "expects",
        "research",
        "development",
        "expense",
        "million",
        "million",
        "quarterly",
        "total",
        "net",
        "revenue",
        "versus",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}